Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19974725 | 0.94 | MEN1 (0.41) | EPHX2EPHX1KMT2AKDM4EMEN1 | |
| SCHEMBL28767035 | 0.86 | EPHX2 (0.40) | EPHX2EPHX1KMT2ABRD4SCN5A | |
| SCHEMBL28767036 | 0.86 | EPHX2 (0.40) | EPHX2EPHX1KMT2ABRD4SCN5A | |
| SCHEMBL21176252 | 0.83 | KDM4E (0.53) | EPHX1KMT2AKDM4EPKMPOLB | |
| SCHEMBL19975153 | 0.81 | EPHX1 (0.45) | EPHX2EPHX1KMT2AMEN1TDP1 | |
| SCHEMBL19975350 | 0.81 | EPHX1 (0.45) | EPHX2EPHX1KMT2AMEN1TDP1 | |
| SCHEMBL21176215 | 0.79 | TDP1 (0.36) | KMT2ATDP1 | |
| SCHEMBL19975303 | 0.79 | MEN1 (0.37) | EPHX2EPHX1KMT2AKDM4EMEN1 | |
| SCHEMBL21176375 | 0.78 | KDM4E (0.50) | EPHX1KMT2AKDM4EPKMMEN1 | |
| SCHEMBL19974955 | 0.77 | EPHX1 (0.33) | EPHX2EPHX1KMT2ABRD4SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| EP-3512836-A1 | ANTIVIRAL COMPOUNDS | Haplogen GmbH (AT) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018050631-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G12A, PLA2G4C | EPHX2 1455/4885EPHX1 372/4885KMT2A 4031/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | EPHX2 1455/4885EPHX1 372/4885KMT2A 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.